2416-2417 / 2953
TROG 96.01: Neoadjuvant HT (3 or 6
months) plus RT vs RT alone
Locally advanced prostate cancer
(T2b-T4; ≈84% high-risk) (n=802)
Randomized
3-month
ADT group
6-month
ADT group
Goserelin 3.6 mg q4w +
flutamide 250 mg tid
for 2 months
Goserelin 3.6 mg q4w +
flutamide 250 mg tid
for 1 month + RT (n=265)
RT alone
(n=270)
Goserelin 3.6 mg q4w +
flutamide 250 mg tid
for 5 months
Goserelin 3.6 mg q4w +
flutamide 250 mg tid
for 1 month + RT (n=267)
Denham JW, et al. Lancet Oncol 2011;12:451-9
ADT, androgen deprivation therapy
HT, hormone therapy; q4w, every 4 weeks
RT, radiotherapy; tid, three times daily